Global Melanoma Therapeutics Market 2015-2019
According to Melanoma Research Foundation, melanoma is usually, but not always, a cancer of the skin. Melanoma is defined as a cancer that occurs in melanocytes (cells that make the pigment melanin). Chest and back in men and legs in women are the most likely parts to be affected with melanoma. CM, MM, and OM are the three major categories of melanoma. The exact etiology of melanoma is unknown. According to the American Skin Association, the incidence of melanoma is increasing worldwide. The median age of diagnosis is 59 years and the median age of death due to melanoma is 67 years.
TechNavio's analysts forecast the Global Melanoma Therapeutics market to grow at a CAGR of 15.40 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Melanoma Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of melanoma that are available in the market. The market is divided into four segments: CM, OM, MM, and Others.
TechNavio's report, Global Melanoma Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Melanoma Therapeutics Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Melanoma Therapeutics Market: Bristol-Myers Squibb Co., F. Hoffmann-La Roche Ltd. and Merck & Co. Inc.
Other Prominent Vendors in the market are: AB Science, Amgen, Bayer, Celgene, Daiichi Sankyo, Eisai, GSK, Novartis, Pfizer, Vical and ZIOPHARM
Commenting on the report, an analyst from Technavio’s team said: “The market is expected to grow steadily during the forecast period because of the increased implementation of combination therapies for late stage treatment of the disease. Combination therapies help in the complete removal of tumors and the destruction of cancerous cells.”
According to the report, the number of people being diagnosed with melanoma has increased worldwide. The high prevalence of melanoma among people has increased the demand for drugs used in the treatment of the disease.
Further, the report states that the availability of alternative treatment options such as chemotherapy, radiation therapy, and surgery limits the consumption of melanoma drugs by the patient population. In radiation therapy, ionizing rays are used to destroy the cancerous cells. Surgery, on the other hand, involves the removal of the tumor and is effective only at the early stages of melanoma.
BMS, Merck, Roche, AB Science, Amgen, Bayer, Celgene, Daiichi Sankyo, Eisai, Galectin Therapeutics, GSK, Novartis, Pfizer, Vical, ZIOPHARM
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook